- Home
- HBNC vs ESPR Comparison
HBNC vs ESPR Comparison
Compare HBNC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | ESPR |
|---|---|---|
| Founded | 1873 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 898.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HBNC | ESPR |
|---|---|---|
| Price | $18.12 | $3.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $19.67 | $6.86 |
| AVG Volume (30 Days) | 320.9K | ★ 6.4M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | $51.78 | $25.45 |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.91 | ★ 2.83 |
| 52 Week Low | $12.70 | $0.69 |
| 52 Week High | $18.70 | $4.13 |
Technical Indicators
Market Signals| Indicator | HBNC | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 53.96 |
| Support Level | $16.90 | $3.72 |
| Resistance Level | $18.70 | $4.13 |
| Average True Range (ATR) | 0.39 | 0.22 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 67.78 | 10.19 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.